prilocaine has been researched along with Erectile Dysfunction in 2 studies
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.
prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.
Erectile Dysfunction: The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xin, ZC | 1 |
| Zhu, YC | 1 |
| Yuan, YM | 1 |
| Cui, WS | 1 |
| Jin, Z | 1 |
| Li, WR | 1 |
| Liu, T | 1 |
| Henry, R | 1 |
| Morales, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)[NCT00556478] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Summary of mean IELT at Baseline and at month 3 during double-blind treatment (NCT00556478)
Timeframe: 3 months
| Intervention | Seconds (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 140.964 |
| Double-Blind Placebo / Open-Label Active | 49.615 |
"To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by:~• change in mean IELT from baseline to during the 3 month double-blind treatment~Results provide are ratio (over the 3 months/baseline)." (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | ratio (Geometric Mean) |
|---|---|
| Double-Blind Active / Open-Label Active | 4.607 |
| Double-Blind Placebo / Open-Label Active | 1.505 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 1.~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 1 month
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Distress | Sexual satisfaction | |
| Double-Blind Active / Open-Label Active | 5.7 | 2.5 | 5.1 |
| Double-Blind Placebo / Open-Label Active | 1.3 | 0.6 | 1.8 |
"Change in the IPE domains of ejaculatory control, distress and sexual satisfaction from Baseline to month 2~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: 2 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Control | Satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 6.5 | 5.8 | 2.9 |
| Double-Blind Placebo / Open-Label Active | 1.4 | 1.3 | 0.7 |
"To Evaluate Efficacy of Treatment With PSD502 Compared With Placebo in Subjects With PE as measured by:~• changes in all 3 IPE domains from baseline to month 3~Ejaculatory control scores range from 4 to 20 with a higher score indicating greater ejaculatory control Sexual satisfaction scores range from 4 to 20 with a higher score indicating greater sexual satisfaction Distress scores range from 2 to 10 with a higher score indicating less distress" (NCT00556478)
Timeframe: Baseline to 3 Months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Ejaculatory control | Sexual satisfaction | Distress | |
| Double-Blind Active / Open-Label Active | 7.2 | 6.6 | 3.5 |
| Double-Blind Placebo / Open-Label Active | 2.2 | 2.1 | 0.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the partner PEP at month 3. Proportion of partners with at least a 1 point category improvement in partner PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of partners (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 68.9 | 64.9 | 62.8 | 66.9 |
| Double-Blind Placebo / Open-Label Active | 40.8 | 50.0 | 32.9 | 50.0 |
Percentage of subjects with mean IELT > 1 minute and >2 minutes during the 3 months of double-blind treatment as measured by the proportion of subjects (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| IELT > 1 minute | IELT > 2 minutes | |
| Double-Blind Active / Open-Label Active | 80.2 | 57.5 |
| Double-Blind Placebo / Open-Label Active | 37.8 | 14.6 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 1. Percentage of subjects with at least a 1 point category improvement in subject PEP domain scores at month 1. (NCT00556478)
Timeframe: 1 month
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 59.6 | 63.4 | 62.7 | 72.0 |
| Double-Blind Placebo / Open-Label Active | 23.5 | 27.2 | 33.3 | 51.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 2. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 2. (NCT00556478)
Timeframe: 2 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 67.5 | 70.1 | 69.4 | 75.8 |
| Double-Blind Placebo / Open-Label Active | 24.7 | 33.8 | 27.3 | 42.9 |
Scores for perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse and interpersonal difficulty related to ejaculation based on the subject PEP at month 3. Proportion of subjects with at least a 1 point category improvement in subject PEP domain scores from baseline to month 3. (NCT00556478)
Timeframe: 3 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Control | Distress | Sexual satisfaction | Interpersonal difficulty | |
| Double-Blind Active / Open-Label Active | 72.4 | 76.9 | 73.7 | 77.6 |
| Double-Blind Placebo / Open-Label Active | 24.1 | 36.7 | 36.7 | 59.5 |
1 review available for prilocaine and Erectile Dysfunction
| Article | Year |
|---|---|
Current therapeutic strategies for premature ejaculation and future perspectives.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antidepressive Agents; Drug Combinations; Ejaculat | 2011 |
1 other study available for prilocaine and Erectile Dysfunction
| Article | Year |
|---|---|
Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study.
Topics: Administration, Topical; Adult; Aerosols; Aged; Anesthetics, Local; Ejaculation; Erectile Dysfunctio | 2003 |